Lung-resident memory CD8 T cells (T RM ) induced by influenza A virus (IAV) that are pivotal for providing subtypetranscending protection against IAV infection (heterosubtypic immunity) are not maintained long term, causing gradual loss of protection. The short-lived nature of lung T RM contrasts sharply with long-term maintenance of T RM induced by localized infections in the skin and in other tissues. We show that the decline in lung T RM is determined by an imbalance between apoptosis and lung recruitment and conversion to T RM of circulating memory cells. We show that circulating effector memory cells (T EM ) rather than central memory cells (T CM ) are the precursors for conversion to lung T RM . Time-dependent changes in expression of genes critical for lymphocyte trafficking and T RM differentiation, in concert with enrichment of T CM , diminish the capacity of circulating memory CD8 T cells to form T RM with time, explaining why IAV-induced T RM are not stably maintained. Systemic booster immunization, through increasing the number of circulating T EM , increases lung T RM , providing a potential new avenue to enhance IAV vaccines.
INTRODUCTION
Seasonal influenza vaccination can provide effective antibody-mediated protection when the main surface antigen [hemagglutinin (HA)] in the vaccine matches that year's circulating influenza A virus (IAV) strains. However, mutations in the globular head region of HA can reduce the neutralizing capacity of vaccine-induced antibodies (1) . In the absence of neutralizing antibodies, IAV-specific memory CD8 T cells, which are maintained systemically and in the lung (2) , correlate with some degree of control of viral titers and reduction of disease symptoms in humans (3, 4) . Mouse models suggest that it is the lung-resident memory CD8 T cells (T RM ) that enable swift and robust protection against IAV infection (5) (6) (7) (8) . Thus, establishing a robust long-term T RM population should be an important goal for an IAV vaccine.
Nonetheless, major knowledge gaps remain concerning lung T RM generation, maintenance, and effector function, especially compared with T RM found in other nonlymphoid tissues such as skin, intestine, and female reproductive tract. Mouse studies suggest that lung T RM share common traits with T RM from other tissues, most notably the expression of the transmembrane C-type lectin CD69 and aE integrin CD103 (7, 9) . However, at the transcriptome level, lung T RM are distinct from skin T RM or intestinal T RM (10) , suggesting differential adaptation to specific microenvironments. One clear difference is that, compared with T RM populations in other tissues (11) , lung T RM have a limited longevity, which strongly correlates with waning of subtypetranscending heterosubtypic immunity to IAV (7) . Therefore, understanding the maintenance of lung T RM may provide information that can be used to extend the life span of this population, thus prolonging heterosubtypic immunity to IAV.
RESULTS

Limited longevity of IAV-induced lung T RM
Local infections, such as herpes simplex and vaccinia virus (Vac), have been used to study the formation and maintenance of T RM in the skin (12) . Skin T RM have a distinct phenotype, coexpressing CD69 and CD103, molecules that have functional roles in retention in the tissues (10) . Moreover, compared with non-T RM , skin T RM express low levels of a key transcription factor, Eomesodermin (Eomes) (13) . The population of skin T RM is stably maintained (11) independently from the circulating memory CD8 T cell pool (12) . In contrast, IAV-specific T RM are lost from the lung with time (7) .
To address this discrepancy under conditions of a fixed T cell receptor (TCR) response, we transferred a small number of naive Thy1.1 P14 transgenic CD8 T cells [specific for the GP33 epitope of lymphocytic choriomeningitis virus (LCMV)] into naive Thy1.2 C57Bl/ 6 recipients followed by epicutaneous (EC) infection of the ear with Vac expressing the LCMV GP33 epitope (Vac-GP33) or intranasal (IN) infection with IAV (PR8-GP33). An intravascular (IV) stain with anti-CD45 antibody was applied before euthanasia to distinguish P14 cells in the tissue (IV − ) from those remaining in small capillary beds (IV + ) (14, 15) . In line with previous work (11) , after an initial decline, the number of Vac-GP33-induced skin T RM (defined as CD69 + CD103 + P14 cells) and the total number of IV − P14 stabilized out to 200 days after infection (Fig. 1, A and B) . We also confirmed that Vac-GP33-induced skin T RM display stable and low expression of Eomes (fig. S1, A and B).
However, lung T RM exhibited a different pattern. After an initial drop, there was an additional~10-fold reduction in numbers of IV − P14 cells from 50 to 200 days after infection (Fig. 1, C and D) . In contrast to the skin, the number of P14 T RM in the lung parenchyma declined~500-fold over the same time period (Fig. 1, C and D) . IAV-induced lung T RM exhibited the same stable and low Eomes expression as Vac-induced skin T RM (fig. S1, C and D). Thus, despite their transience, IAV-generated lung IV − CD69 + CD103 + CD8 T cells represented bona fide T RM . Waning of lung T RM was not limited to P14 TCR transgenic cells or recombinant IAV because endogenous T RM specific for an influenza nucleoprotein-derived epitope (NP366) also underwent~500-fold decrease over the course of 200 days after IN PR8 infection (Fig. 1 , E and F). The marked decline of IAV-induced lung T RM was not virus strain-dependent because NP366-specific lung T RM declined in a similar manner by day 125 after IN infection with X31 IAV (Fig. 1G) . Moreover, the observation of limited lung T RM longevity extended to respiratory infections other than IAV. IN infection of P14 recipients with Vac-GP33 induced GP33-specific and endogenous Vac B8R-specific lung T RM responses, which declined in a similar fashion as IAV-induced lung T RM ( fig. S2, A to D) . Thus, the differences between lung and skin T RM are not explained by the use of different viruses for each organ.
Last, we confirmed that waning of IAV-induced lung T RM correlated with loss of CD8 T cell-mediated heterosubtypic protection. Primary exposure to H3N2 X31 IAV induced protection against challenge with heterosubtypic H1N1 PR8 IAV performed 30 days after X31 infection, measured by reduction of lung PR8 virus titers (Fig.  1H) . Depletion of CD8 T cells rendered X31-immunized mice incapable of controlling PR8 virus titers. Heterosubtypic protection was completely lost at 125 days after initial X31 infection, which correlated with a substantial decline in lung T RM (Fig. 1, G and H) .
In summary, these data showed that, in models of fixed TCR specificity with P14 TCR transgenic T cells, skin and lung T RM populations exhibit differences in persistence and confirmed the observation that IAV-specific T RM populations were not stable in the lung (7). In turn, the loss of T RM correlated with reduced CD8 T cell-dependent control of heterosubtypic IAV challenge (7), emphasizing the importance of understanding why the numbers of lung T RM decreased over time.
Apoptosis, rather than migration, drives the loss of IAV-generated T RM from the lung To assess the possibility that some T RM migrate out of the lung and to determine the persistence of lung T RM , we labeled lung-residing cells using an in vivo carboxyfluorescein diacetate succinimidyl ester (H) C57Bl/6 mice were infected with H3N2 X31 IAV and, 30 or 125 days later, exposed to heterologous challenge with H1N1 PR8. D30 challenge was performed with and without CD8 T cell depletion. Lung PR8 virus titers measured in naive and X31-infected mice. n = 4 to 5 mice per group. Representative of two independent experiments. Error bars represent means ± SEM. **P < 0.01; ****P < 0.0001, multiple comparison one-way ANOVA.
(CFSE) labeling approach (16, 17) . IN inoculation of CFSE into mice previously infected with PR8-GP33 labeled all P14 cells in the lung parenchyma but led to a negligible CFSE staining of P14 cells in the draining lymph nodes and the spleen ( fig. S3 ), allowing for specific fate tracking of lung T RM . In vivo CFSE labeling of lung IV − P14 generated by intraperitoneal (IP) infection with LCMV Armstrong, an approach that does not generate lung T RM ( fig. S4 ), showed loss of labeled cells within 24 hours (Fig. 2, A and B) . In contrast, IV − P14 cells generated through IN PR8-GP33 infection persisted with a halflife of~5 days (Fig. 2, A and B) . Loss of CFSE did not result from proliferation, because no discernable 5-bromo-2′-deoxyuridine incorporation was detected in the CFSE lo cells during this time period ( fig. S5 ). To assess whether T RM are lost by migration, we blocked entrance of lung T RM to the afferent lymphatics using the S1PR1 agonist FTY720 (18) . FTY720 treatment did not prevent the loss of CFSE + P14 from the lung parenchyma (Fig. 2C) , strongly suggesting that migration to the afferent lymph was not the primary mode of loss of IAV-generated T RM .
Alternatively, impaired maintenance of lung T RM could result from an increased apoptosis. In support of this notion, we observed a higher percentage of IAV-induced IV − lung memory P14 expressing active caspases 3/7 (Flica stain) relative to IV + lung memory P14, suggesting elevated proapoptotic activity in tissue-embedded cells (Fig. 2D ). Increased apoptosis is not a general feature of T RM , because we observed no difference in Flica staining between skin IV − memory P14 cells and their IV + (blood) counterparts (Fig. 2D) . Furthermore, lung IV − CD103 + P14 cells displayed higher caspase 3/7 activity than did CD103 − P14 cells (Fig. 2E ). In addition, protein expression of the antiapoptotic molecule Bcl-2 was substantially reduced in IV − memory P14 cells relative to the IV + cells in the lung or in blood (Fig. 2F) . Decreased Bcl-2 protein expression in IV − relative to IV + memory P14 cells was also observed at day 90 after infection, suggesting that compromised survival may be a sustained characteristic of lung T RM ( fig. S6 ). In contrast, skin IV − and IV + circulating memory P14 cells exhibited similar levels of Bcl-2 expression at day 30 after infection ( Fig. 2F) . Notably, within the lung IV − P14 population, CD103 + cells had substantially decreased Bcl-2 expression compared with IV + P14, whereas CD103 − P14 cells had similar Bcl-2 expression to IV + cells (Fig. 2G) . Last, we assessed the maintenance of mitochondrial membrane potential (DY mito) to evaluate the proapoptotic state of memory CD8 T cells in the lung after IAV infection (Fig. 2, H and  I ). In line with increased Flica staining and decreased Bcl-2 expression, a larger fraction of lung IV − P14 cells exhibited decreased DY mito fluorescence compared with IV + P14 (Fig. 2H ). In addition, IV − CD103 + cells showed lower DY mito fluorescence compared with their IV − CD103 − counterparts (Fig. 2I) . Together, these data showed that lung T RM were prone to apoptosis, suggesting that cell death, rather than migration to draining lymph nodes, contributed to the limited longevity of this CD8 T cell population.
Lung T RM maintenance is linked to persistence of circulating memory CD8 T cell pool Despite the increased signature of apoptosis in the T RM population (Fig. 2, D to I ) and a steady decline of CFSE-labeled T RM P14 cells in the lung parenchyma (Fig. 2B) , the total number of T RM did not decrease over the 6-day CFSE chase interval ( fig. S7 ). As depicted in . S5 ), these data suggest de novo generation of lung T RM from a memory population outside of the lung parenchyma. Given previous reports showing continuous recruitment of circulating memory CD8 T cells into the lung even weeks after the clearance of the infection (19, 20) , we hypothesized that lung T RM were continuously formed from circulating precursors. Systemic antibodymediated depletion has been routinely used to show that, in most tissues, T RM are maintained independently from the circulating memory population (21, 22) . However, antibody depletion of the systemic memory CD8
+ T cell population also depleted lung T RM ( fig. S8 ). As an alternative, we used a system where depletion is based on cellular interactions (21) . Male and female P14 cells were transferred in a 1:1 ratio into female recipients, which were subsequently infected either IN with PR8-GP33 or EC with Vac-GP33 (Fig. 3B) . Male P14 cells underwent initial expansion in numbers like female P14 cells but were rejected from the circulation after 2 weeks (Fig. 3C ). As previously reported (21) , male P14 cells in the skin were detectable for several weeks after they were systemically rejected (Fig.  3 , D and E), indicating maintenance of skin T RM without input from circulating memory CD8 T cells. Male P14 cells were also detectable in the lung parenchyma for several weeks after systemic rejection (Fig. 3 , D and E), suggesting that the parenchyma provides a niche that shields male P14 from deletion. However, the 1:1 ratio is not maintained long term, and male P14 cells are progressively lost from the lung parenchyma (Fig. 3, D and E). Although we cannot formally exclude the possibility that anti-male cytotoxic T lymphocytes gradually killed male P14 cells, in conjunction with the observed apoptosis of lung T RM (Fig. 2 , D to I), these data strongly suggested that lung T RM were not adequately maintained without input from the circulating memory CD8 T cell population and that maintenance of the lung T RM pool required continuous recruitment of circulation-derived precursors. Consistent with this hypothesis, blocking the entrance of circulating memory P14 into the lung parenchyma by administration of pertussis toxin (PTx) 3 weeks after infection significantly (P < 0.05) reduced the number of T RM in the lung parenchyma 1 week later. In contrast, PTx treatment did not affect the number of systemic memory P14 in the spleen (Fig. 3F ). These data are consistent with the requirement for a continuous influx of memory P14 cells from the circulation to maintain stable lung T RM numbers over the short-term period.
Continuous seeding of lung T RM by precursors from the circulation is influenced by the lung cytokine milieu Continuous formation of lung T RM has been proposed (23, 24) and was thought to be driven by persisting IAV antigen. Antigen has been shown to persist for at least 2 months in the lung after IAV infection (24) , making this an attractive explanation for the continuous formation but also the eventual disappearance of lung T RM (7) . To confirm continuous recruitment of circulating memory CD8 T cells to the lung and to assess whether persisting antigen drives conversion of recruited memory CD8 T cells to lung T RM , we adoptively transferred spleen-derived (CD69 − CD103 − ) memory P14 cells that were generated by X31-GP33 infection into naive, PR8 (no antigen)-infected, or PR8-GP33 (antigen)-infected mice (Fig. 4A) . Analysis of the lung 1 week after transfer revealed de novo generation of T RM in all groups of mice (Fig. 4B) . A substantially larger fraction of transferred P14 cells entered the lung parenchyma of PR8-and PR8-GP33-infected mice compared with naive mice (Fig. 4C ). This suggested that the lung environment still drives additional recruitment of P14 cells into the parenchyma weeks after IAV infection, but this process does Representative of three independent experiments. Error bars represent means ± SEM. P < 0.0001, multiple comparison one-way ANOVA.
not require cognate antigen. In addition, conversion to a T RM phenotype was higher in PR8-and PR8-GP33-infected mice compared with naive mice, suggesting that the post-IAV lung environment was permissible to de novo T RM generation weeks after infection (Fig. 4D) . However, no difference in P14 conversion to T RM was observed between PR8-and PR8-GP33-infected mice. Thus, the IAV-experienced lung contains cues other than antigen to drive formation of lung T RM from circulating precursors. Cytokines such as transforming growth factor-b, interleukin-33 (IL-33), and tumor necrosis factor (TNF) have been implicated in formation of T RM (10, 25) , with IL-33 specially implicated in the function of lung-resident innate lymphocyte cells (26) . Because IAV infection increased lung IL-33 (27) and TNF (28) ( fig. S9 ), we transferred memory P14 CD8 T cells derived from spleens of PR8-GP33-infected mice into naive recipient mice (Fig. 4E) that were treated or not with blocking (anti-IL-33R) or neutralizing (anti-TNF) antibodies before analyses on day 7 (Fig. 4E) .
Blocking the IL-33 receptor reduced the number IV − P14 in the lung parenchyma (Fig. 4 , F and G) but did not affect conversion to a T RM phenotype (Fig. 4, F and H) . On the other hand, neutralization of TNF reduced both the accumulation (Fig. 4, F and G) of P14 cells in the lung parenchyma and acquisition of T RM phenotype (Fig. 4, F and  H) , suggesting a role for this cytokine in formation and maintenance of lung T RM .
Thus, our data show that the maintenance of IAV-induced lung T RM CD8 T cell population critically depended on the circulatory CD8 T cell memory pool. Continuous seeding of the lung T RM niche by circulating memory CD8 T cells appeared to be antigenindependent and at least partially driven by local inflammatory cues (e.g., IL-33 and TNF). 
IAV-induced circulating memory CD8 T cells lose the capacity to form T RM over time
The capacity of circulating memory CD8 T cells to replenish lung T RM contradicts the observation that T RM are lost by about 6 months after infection. Therefore, we hypothesized that, with time, circulating IAV-specific memory CD8 T cells lose their intrinsic capacity to generate T RM . To probe this, we transferred memory P14 cells isolated from spleens of mice infected with PR8-GP33 for 20 to 30 days (early memory) or >100 days (late memory) into recipient mice infected with PR8 virus 21 days before (Fig. 5A) . Late memory P14 cells showed a marked decrease in accumulation in the lung parenchyma relative to early memory P14 (Fig. 5B) . Furthermore, late memory P14 displayed poor conversion to a T RM phenotype compared with early memory P14 (Fig. 5C ). These data suggest that circulating memory CD8 T cells intrinsically lose the capacity to form lung T RM over time, independent of the change in the local inflammatory cues.
To assess the molecular signatures that could potentially explain the difference between early and late circulating memory CD8 T cells in forming lung T RM , we analyzed genome-wide mRNA expression in early (20 to 30 days after infection) and late (>100 days after infection) spleen-derived memory P14 generated by IN PR8-GP33 infection. Many genes (2657; based on ≥1.25-fold difference, P < 0.05) were differentially expressed in late versus early memory P14, with a similar number being up-regulated (1326) or down-regulated (1331) (fig. S10A) . Notably, transcriptome analysis suggested differential expression of three transcription factors identified as master regulators of T RM formation: mRNA for Eomes (1.68× up-regulated in late versus early memory P14), Blimp-1 (2.19× down-regulated in late versus early memory P14), and Hobit (1.21× down-regulated in late versus early memory P14) (13, 29) . Real-time quantitative polymerase chain reaction (qPCR) analysis performed on mRNA isolated from early and late IAV-induced memory P14 demonstrated increased Eomes (P < 0.0001) and decreased Blimp-1 (P = 0.021) and Hobit (P = 0.0033) mRNA expression in late versus early splenic memory P14 cells (Fig. 6A) . Intracellular protein staining confirmed that a substantially higher percentage of late compared with early memory P14 cells up-regulated Eomes (Fig. 6B) . Combined, these data show that the transcription factor profile of late memory P14 cells was incompatible with acquisition of T RM phenotype. In addition, ingenuity pathway analyses revealed substantial alterations in a leukocyte migration gene set between late and early memory P14, represented by 158 genes (P = 5.48 × 10 −25 ) (table S1). Gene set enrichment analysis showed that leukocyte migration-associated genes were significantly negatively enriched (false discovery rate < 0.01; normalized enrichment score, −1.45) in late memory P14 (fig. S10B), suggesting some compromise in the ability to migrate to tissues. To further refine our gene analysis and focus only on T lymphocyte migration, we performed a literature-based selection of genes from the leukocyte migration pathways based on (i) expression by T lymphocytes and (ii) association with cell movement, migration, or chemotaxis. This approach shortlisted 70 genes that were further divided into specific categories, based on the function of their protein products (table S2) . Notably, expression of most of these genes (>75%) was down-regulated in late versus early memory P14 ( fig. S10C) . Combined, the gene expression signatures strongly suggested that, with time, memory CD8 T cells down-regulate the complex functional network of molecules collectively controlling cell migration to peripheral tissues. In turn, the reduced capacity of late memory CD8 T cells to enter lung tissue likely contributed to the decline in the T RM population.
Our data showed that, with time, IAV-induced circulating memory CD8 T cells lose the capacity to form de novo lung T RM . We propose that inefficient conversion to T RM , based on an unfavorable transcription factor landscape, together with the decreased recruitment to the lung tissue due to loss of migratory capacity in late circulating memory CD8 T cells, underlies the waning of lung T RM .
Circulating effector memory CD8 T cells are precursors of IAV-induced lung T RM Analyses of the leukocyte migration genes revealed that two of the relatively few mRNAs enriched in late memory P14 cells were those coding for CCR7 and CD62L ( fig. S10C ), well known to be required for homing to secondary lymphoid tissue and as canonical markers of central memory CD8 T cells (T CM ) (30) . In addition, we observed that the vast majority (>85%) of PR8-GP33-induced circulating memory P14 cells up-regulated CD62L by day 90 after infection. However, the T RM population in the lung was composed of predominantly CD62L
− cells (Fig. 7A ). Because T RM P14 had a surface phenotype like effector memory T cells (T EM ) (CD62L − ), it was very likely that they were recruited from the circulating T EM pool, although active down-regulation of CD62L upon recruitment to the lung could not be ruled out. To discriminate between these possibilities, we isolated PR8-GP33-induced splenic memory Thy1.1 P14 cells on day 65 after infection (when an optimal ratio of CD62L + and CD62L − P14 was observed), separated them into enriched CD62L + and CD62L − subpopulations, transferred them into mice infected IN with PR8 IAV 21 days earlier (Fig. 7B) , and assessed their capacity to convert into T RM 7 days later. Notably, the T RM master regulator Eomes was differentially expressed in the donor populations, with CD62L + P14 (blue) being Eomes hi and CD62L − (red) expressing less Eomes (Fig. 7C) . The vast majority (89%) of P14 cells isolated from the lungs of CD62L + recipients were CD62L + , whereas most (76%) of the P14 cells in the lungs of CD62L − recipients were CD62L − (Fig. 7D) . This finding strongly suggested that down-regulation of CD62L after cell entry into the lung was (Fig. 7E) . A discernable fraction of IV − P14 (~10%) formed CD69 + CD103 + lung T RM in the CD62L − recipients (Fig. 7F) . In contrast, we did not detect any lung T RM P14 in CD62L + recipients (Fig. 7F) . Thus, our results identified circulating T EM as the precursors for de novo formation of IAV-specific lung T RM . These data suggested the intriguing hypothesis that expansion of the circulating T EM population induced by IAV infection could increase numbers of lung T RM . To test this hypothesis, we exposed PR8-GP33 immune or naive P14 recipient mice to systemic infection with recombinant Listeria monocytogenes expressing GP33 (LM-GP33) or an unrelated epitope derived from the Plasmodium berghei TRAP protein (LM-TRAP) (31, 32) 45 days after the initial PR8-GP33 infection (Fig. 8A ). Mice were sacrificed 30 days after the systemic boost (75 days after initial PR8-GP33 infection), and circulating and lung P14 cells were analyzed (Fig. 8A) . As predicted, systemic boosting with LM-GP33 enhanced the fraction of circulating T EM P14 cells (~84% were CD62L − ), in sharp contrast to all the other immunization groups where circulating T CM P14 dominated the response (Fig. 8, B and C). As depicted in Fig. 8D , the most marked result of systemic boosting with LM-GP33 was an~120× increase in the frequency of lung P14 memory cells, relative to nonboosted or LM-TRAP-infected controls. Notably, naive mice that received the systemic LM-GP33 boost generated a circulating memory P14 population but did not generate a detectable population of lung P14 T RM (Fig. 8, D and E) . In addition, boosting IAV immune mice with LM-TRAP did not alter lung P14 T RM numbers. However, in support of our hypothesis, the large increase in circulating T EM in PR8-GP33 immune mice boosted with LM-GP33 was associated with an~10-fold increase in lung P14 T RM at 30 days after boost (Fig. 8, D and E) . The increase in lung T RM did not result from a marked increase in frequencies of CD69 + CD103 + P14 cells in the lung IV − population but rather from an increase in the total number of lung IV − P14 cells in the LM-GP33-boosted mice (Fig. 8, D and E) . Thus, systemic boosting of IAV-induced memory CD8 T cell responses substantially increased the frequency of circulating T EM , which in turn enhanced the seeding of IAV-experienced memory CD8 T cells in the lung. The sustained ability of the lung environment to convert T EM to T RM , in the context of a larger number of lung parenchymal T EM , resulted in a substantial increase in the number of lung T RM .
DISCUSSION
Here, we show that maintenance of lung T RM , in contrast to wellstudied T RM populations in skin, is driven by a dynamic equilibrium between apoptosis in the lung parenchyma and reseeding from the circulatory T EM population. However, the capacity of the circulating memory CD8 T cell population to home to the lung and convert to T RM is lost with time, leading to the progressive loss of the lung T RM population and heterosubtypic protection. Of relevance for vaccine design, we show that increasing circulating T EM through systemic boosting can increase the size of the lung T RM pool, potentially prolonging heterosubtypic immunity.
Our data suggest that lung T RM are continuously being replenished from CD69 − CD103 − circulating memory CD8 T cells in an antigen-independent and inflammation-dependent manner. These results are in concordance with earlier reports using parabiotic mice (24, 33) or adoptive transfers (5, 6), which show that memory CD8 T cells can migrate into the lung during the steady state and in the absence of antigen. However, these earlier studies did not use an IV stain to distinguish CD8 T cells in the lung parenchyma from those in the lung vasculature and did not use the markers to distinguish whether the lung CD8 T cells were transient effector memory subsets or became genuine T RM . The main findings of this study stem from comparison of T RM in the skin and the lung, induced by recombinant Vac-GP33 and PR8-GP33, respectively. Although this system allowed us to compare the responses of the same TCR transgenic T cells to the same antigen, the antigen was delivered by viruses with distinct biological interactions with the host. While acknowledging this complexity, we also show that T RM , specific for the same GP33 epitope or the endogenous Vac B8R epitope, also wane with time after respiratory Vac-GP33 infection, suggesting that the transient nature of lung T RM is mainly driven by the local tissue environment. Whether this finding will extend to all respiratory virus infections remains to be determined. Experimental support for the notion that circulating T EM 
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can home to the IAV-conditioned lung and convert to lung T RM was obtained from multiple approaches, including pulse chase of lung T RM with lung CFSE labeling and the progressive loss of male P14 T RM in IAV-GP33-infected female mice, in contrast to their skin T RM counterparts. In these studies, we cannot formally rule out that some loss of CFSE-labeled lung T RM could occur through migration into the airways or that loss of male T RM in the lung could result from rejection by male-specific T cells reaching the lung parenchyma of the female mice. However, we also found that PTx treatment, which prevents migration of circulating memory CD8 T cells into tissues, also reduced lung T RM and that CD69 − CD103 − splenic T EM homed to the lung and converted to T RM after adoptive transfer. Thus, the preponderance of evidence is consistent with the notion that the longevity of lung T RM after IAV infection involves replenishment from the pool of circulating memory CD8 T cells.
In addition to apoptosis of lung T RM and their replenishment from the circulating memory populations, we also show that circulating memory CD8 T cells lose the capacity to form lung T RM with time.
Our data support a model where decreasing cellular input, in combination with the loss of existing populations through apoptosis, underlies the relatively slow decline of T RM in the lungs. We propose that, with time, circulating memory CD8 T cells acquire a transcription factor profile that may not be permissible for conversion to T RM in the lung (up-regulated Eomes and down-regulated Blimp-1 and Hobit) (13, 29) . In addition, bioinformatic analyses emphasize a loss in general tissue migratory capacity in memory CD8 T cell populations with time, which supports our observation that circulatory memory CD8 T cells eventually lose the capacity to populate lung parenchyma.
Last, we identify the circulating T EM pool as the main source of precursors for lung T RM . These results suggest that the progressive shift of systemic memory CD8 T cells toward T CM , and concurrent loss of T EM populations, underlies the slow decay of IAV-induced lung T RM , although time-dependent changes in the T EM subset may also contribute to loss of T RM . Consistent with either notion, we show that systemic booster vaccination, through expansion of the circulating T EM population, can increase the numbers of lung T RM CD8 T cells. Despite the >100× increase in frequency of lung CD8 T cells, numbers of T RM increased only~10-fold, suggesting that optimization of the booster approach may be possible.
In conclusion, we identify several key features of IAV-induced lung T RM maintenance that differentiate them from maintenance of T RM populations in other microenvironments. In addition, we provide an explanation for the gradual decline of lung T RM and loss of heterosubtypic protection with time, based on loss of these cells by apoptosis and the diminishing capacity of circulating memory CD8 T cells to home to the lung and convert to T RM . Further, we also show that waning lung T RM can be at least partially restored by systemic boosting to increase the size of the circulating T EM populations, suggesting that longevity of lung T RM may be manipulated through rational vaccination. 
MATERIALS AND METHODS
Study design
The main aim of the study was to explain the gradual waning of IAVinduced lung T RM , which correlates with loss of heterosubtypic protection. For this purpose, we adopted a mouse model of IAV infection. The initial phase of the study confirmed the appropriateness of our model and developed approaches to evaluate the biological status and longevity of IAV-induced lung T RM . Subsequent studies addressed the biology underlying recruitment and conversion of circulating memory CD8 T cells into lung T RM , the waning of this ability with time, and the capacity of systemic booster immunization to restore lung T RM . All experiments were performed at least twice. The study involved sublethal infections with IAV, Vac, or euthanasia before excessive body weight loss after IAV challenge; thus, no predetermined outcomes, such as weight loss, were used in the study, and no outliers were excluded from the data analyses.
Mice
C57Bl/6 mice were originally derived from the National Cancer Institute (Fredericksburg, MD), and a colony is maintained in house. P14 transgenic mice (on a C57Bl/6 background) were acquired from the Jackson Laboratory. All animal studies and procedures were approved by the University of Iowa Animal Care and Use Committee, under U.S. Public Health Service assurance, Office of Laboratory Animal Welfare guidelines.
Viral and bacterial infections
Influenza A/PR/08/34 H1N1 (PR8) and recombinant PR8 or X31 expressing GP33 (34, 35) were grown in chicken eggs. Allantoic fluid was diluted in phosphate-buffered saline (PBS), and mice received a sublethal dose [2 × 10 4 TCID 50 (median tissue culture infectious dose)] while lightly anesthetized. EC infection with Vac expressing GP33 (Vac-GP33, a gift by E. J. Wherry, University of Pennsylvania) was performed by applying 5 × 10 6 plaque-forming units (PFU) of the virus on the center of the ear pinna, followed by poking 25 times with 27-gauge needle. For IN infection with Vac-GP33, mice were inoculated with 10 7 PFU of the virus. LCMV Armstrong infections were performed by IP injection of 2 × 10 5 PFU of the virus. Systemic booster/ mock booster immunizations were performed by IV injection of 10 7 colony-forming units of recombinant attenuated L. monocytogenes expressing GP33 (LM-GP33) or a P. berghei TRAP-derived epitope (LM-TRAP) (31) .
Influenza protection and lung virus titers
C57Bl/6 mice were infected with X31 IAV (a reassortant IAV with six internal genes of PR8 and the HA and neuraminidase of H3N2 A/Aichi/ 2/68). Heterosubtypic protection by early memory CD8 T cells was assessed 30 days after infection. Half of the mice were inoculated with CD8 depleting antibody, clone 2.43 (400 mg IP and 100 mg IN), whereas the rest of the animals were treated with equal amounts of rat immunoglobulin G (IgG) control antibody. Two days after depletion, X31-immune mice and naive control animals were IN challenged with heterosubtypic PR8 (H1N1) virus. Lungs were harvested, and virus titers were assessed 3 days after challenge. Protection by late memory CD8 T cells was assessed in the same way, with PR8 challenge performed >100 days after the initial X31 infection.
Intravascular staining and tissue preparation
Mice were intravenously injected with 2 mg of anti-CD45.2-allophycocyanin (clone 104, BioLegend) in PBS. After 3 min, mice were euthanized, and whole lung or skin (ear) was isolated. Lung and skin were cut into small pieces and incubated for 1 hour in a mixture of collagenase (125 U/ml) and deoxyribonuclease (0.1 mg/ml) at 37°C. Single-cell suspensions were obtained by forcing the organs through a 70-mm mesh screen. Erythrocytes were lysed using Vitalyze (BioE), and leukocytes were purified with 35% Percoll (GE Healthcare) in Hanks' balanced salt solution.
Statistical analysis
Comparison between two study groups was statistically evaluated by unpaired, two-tailed t test. Comparisons between more than two groups (single factor) were evaluated using one-way analysis of variance (ANOVA) with Tukey's multiple comparison post hoc test. Twoway ANOVA with Sidak's multiple comparison post hoc test was used to evaluate comparison between more than two groups at different time points (multiple factors). In all the tests performed, statistical significance was quantified as *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Statistical analyses were performed using GraphPad Prism 7 software. Additional statistical information including P values is listed in table S3.
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